首页> 外文期刊>Journal of Clinical Pathology >Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation
【24h】

Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation

机译:表皮生长因子受体(EGFR)在乳腺上皮细胞分化为乳腺高级别导管癌中的频繁过表达

获取原文
获取原文并翻译 | 示例
       

摘要

Aims: To evaluate the expression of common biological markers and the epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation (DCMDs). Materials/methods: Thirty DCMDs were clinicopathologically and immunohistochemically analysed and compared with 36 control cases of high grade conventional invasive ductal carcinoma (IDC). Results: EGFR, HER2eu, oestrogen receptor, progesterone receptor, and p53 expression was seen in 21, one, three, four, and 20 of the 30 DCMDs, compared with eight, nine, 18, 17, and five of the 36 conventional IDCs (p < 0.05), respectively. In 16 of the 30 DCMDs, metastases were found in the brain, lung, bone, and liver, within a maximum of 47 months (mean, 13.9) after initial surgery, whereas only four of the 36 conventional IDCs metastasised to the lung and bone within a maximum of 27 months (mean, 18.0) after initial surgery (p = 0.0001). There was a significant difference in disease free survival between DCMD and conventional IDC (p = 0.001). EGFR was frequently overexpressed in DCMD compared with conventional IDC, whereas the expression of HER2eu and hormone receptors was lower in DCMD. Fluorescent in situ hybridisation revealed that the mean EGFR to chromosome 7 centromere (CEP7) ratio of the 24 DCMD cases available for evaluation was 1.03, and EGFR gene amplification was not detected in the 21 DCMD cases with EGFR overexpression. Conclusion: Immunohistochemistry for myoepithelial markers and EGFR is useful for the accurate diagnosis and molecular target treatment of high grade DCMD.
机译:目的:评估在具有肌上皮分化(DCMD)的乳腺高级别导管癌中常见生物学标志物和表皮生长因子受体(EGFR)的表达。材料/方法:临床病理和免疫组织化学分析了30例DCMD,并与36例常规常规浸润性导管癌(IDC)对照病例进行了比较。结果:30个DCMD中有21个,1、3、4和20个中见到EGFR,HER2 / neu,雌激素受体,孕激素受体和p53表达,而36个中有8、9、18、17和5个见到常规IDC(p <0.05)。在30个DCMD中,有16个在初次手术后最多47个月(平均13.9)内在脑,肺,骨骼和肝脏中发现了转移,而在36个常规IDC中仅有4个转移到了肺和骨骼。初次手术后最多27个月(平均18.0)内(p = 0.0001)。 DCMD与常规IDC之间的无病生存率存在显着差异(p = 0.001)。与常规IDC相比,EGFR在DCMD中经常过表达,而HER2 / neu和激素受体的表达在DCMD中较低。荧光原位杂交显示,可评估的24例DCMD病例中,平均EGFR与7号染色体着丝粒(CEP7)之比为1.03,在21例EGFR过表达的DCMD病例中未检测到EGFR基因扩增。结论:肌上皮标志物和EGFR的免疫组织化学对高级别DCMD的准确诊断和分子靶标治疗有帮助。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号